Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of diseases, with a focus on genetic diseases. The company's product, Mepsevii (vestronidase alfa), is approved for the treatment of children and adults with Mucopolysaccharidosis VII. The company's biologics pipeline includes burosumab in clinical development for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia. The company's substrate replacement therapy pipeline includes UX007 in clinical development for the treatment of long-chain fatty acid oxidation disorders and glucose transporter type-1 deficiency syndrome.
  • TickerRARE
  • ISINUS90400D1081
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for RARE

ValuEngine Rating and Forecast Report for RARE

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Aug 15

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Aug 15

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

1 director sold

A director at Ultragenyx Pharmaceutical Inc sold 19,550 shares at 53.970USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The...

ValuEngine Rating and Forecast Report for RARE

ValuEngine Rating and Forecast Report for RARE

ValuEngine Rating and Forecast Report for RARE

ValuEngine Rating and Forecast Report for RARE

ValuEngine Rating and Forecast Report for RARE

ValuEngine Rating and Forecast Report for RARE

ValuEngine Rating and Forecast Report for RARE

ValuEngine Rating and Forecast Report for RARE

ValuEngine Rating and Forecast Report for RARE

ValuEngine Rating and Forecast Report for RARE

MarketLine Department

Alexion Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Alexion Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Alexion Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its com...

GlobalData Department

Ultragenyx Pharmaceutical Inc (RARE) - Medical Equipment - Deals and Alliances Profile

Summary Ultragenyx Pharmaceutical Inc (Ultragenyx) is a biotechnology company that develops life-enhancing therapeutics for rare and ultra-rare genetic diseases. Its only marketed product, Mepsevii (vestronidase alfa) is the first indication approved for the treatment of adults and children with Mucopolysaccharidosis (MPS) VII (Sly syndrome). The company’s pipeline comprises Burosumab (KRN23 or UX023), a fully human monoclonal antibody in Phase 3 for the treatment of X-linked hypophosphatemia (XLH); and Burosumab in Phase 2 for the treatment of tumor-induced osteomalacia (TIO); UX007 in Phase...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • John Betz

Vermilion Compass: Weekly Equity Strategy

• Bullish but selective. As we alluded to last week, our long-term bullish outlook remains intact. However, looking through the charts we find a growing list of extended and parabolic patterns. While we continue to remain bullish, we acknowledge the likelihood of backing and filling, or a pause, is building. The further a stock's price action moves from its 200-day, the greater the possibility of a corrective reversion to the mean, or pullback. In last week's Compass our example was Boeing Corporation (BA). The stock is trading 40% above its 200-day moving average, and this rate of momentum i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch